ORAL BCX 34 IN T CELL MALIGANCIES

BCX-34是由BioCryst制药公司开发的一种实验性药物，正在评估用于治疗T细胞介导性疾病。它已经在动物身上进行了广泛的测试，以表明它是安全的。口服BCX-34已经在3名患者身上进行了初步研究，以评估其安全性。在单次口服剂量和5天的口服疗程中，没有发现与药物有关的不良事件。这将是研究这种药物对人类影响的第一项长期研究。这项试验的目的是确定治疗反应所需的最有效和毒性最小的药物剂量。这将通过评估血液和尿液中的药物水平，监测血细胞计数是否存在潜在的异常，以及评估皮肤和其他器官对治疗的反应来衡量。

BCX-34 is an experimental drug developed by BioCryst Pharmaceuticals Inc., and is being evaluated for use in the treatment of T-cell mediated disases. It has been tested extensively in animals to show that it is safe. Oral BCX-34 has been tested on 3 patients in an initial study to evaluate its safety. During the administration of a single oral dose and a 5 day oral course, no drug related adverse events were noted. This will be the first long term study investigating the effects of this drug in humans. The purpose of this trial is to determine the most effective and least toxic dose of medication needed for a therapeutic response. This will be measured by evaluating levels of drug in the blood and urine, monitoring blood counts for potential abnormalities and assessing the response of the skin and other organs to therapy.